Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company dedicated to discovering and developing innovative targeted therapies that address the unmet needs of cancer patients. The company leverages its proprietary product engine to target frontier oncology pathways, with a strong focus on the RAS and mTOR signaling pathways, which are crucial for cancer growth and survival. Revolution Medicines’ approach draws inspiration from nature and evolution, harnessing insights from natural products to guide the discovery and development of small molecules that modulate key cancer targets.
The company’s research and development pipeline features several promising candidates, including RMC-4630, a SHP2 inhibitor, and a portfolio of RAS(ON) inhibitors such as RMC-6236, RMC-6291, and RMC-9805. These novel therapies aim to inhibit the active form of RAS proteins, which are common drivers in numerous cancer types. Revolution Medicines is also advancing the SOS1 and 4EBP1/mTORC1 programs, which hold significant potential in combination treatment strategies.
Recent achievements highlight the company’s progress in clinical development. Notably, the RMC-6236 Phase 1/1b trial demonstrated promising clinical activity and a favorable safety profile in patients with advanced solid tumors harboring KRAS mutations. The trial results showed an objective response rate of 38% in non-small cell lung cancer (NSCLC) and 20% in pancreatic ductal adenocarcinoma (PDAC), with disease control rates of 85% and 87%, respectively.
In October 2023, Revolution Medicines announced a pivotal milestone with the merger with EQRx, Inc., enhancing its financial position and enabling further investment in its clinical programs. The merger is expected to add approximately $1.1 billion in net cash proceeds, supporting the advancement of their RAS(ON) and RAS Companion Inhibitors. Dr. Sandra Horning, a renowned oncologist and former Genentech executive, joined the board of directors, bringing invaluable experience to the company.
Revolution Medicines continues to engage the scientific community and stakeholders through presentations at major conferences and investor webcasts. The company remains committed to advancing its robust pipeline of oncology therapies, aiming to revolutionize the treatment landscape for RAS-addicted cancers and improve outcomes for cancer patients worldwide.
Revolution Medicines has announced the dosing of the first patient in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The global, randomized, open-label study will evaluate RMC-6236 monotherapy against standard chemotherapy in approximately 460 patients worldwide who have received one prior line of therapy.
The study focuses on patients with PDAC harboring specific RAS mutations. Primary endpoints are progression-free survival (PFS) and overall survival (OS) in the core patient population. This milestone marks a significant step in Revolution Medicines' mission to revolutionize treatment for RAS-addicted cancers, particularly PDAC, which has a five-year survival rate of only 3% in metastatic cases.
Revolution Medicines (Nasdaq: RVMD) announced seven presentations at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. Two late-breaking presentations will feature new clinical data on pancreatic ductal adenocarcinoma (PDAC) patients treated with RMC-6236 and RMC-9805. The presentations include:
1. Updated safety and efficacy data from the RMC-6236 monotherapy study
2. Initial safety and antitumor activity data from the RMC-9805 first-in-human monotherapy study
3. Five additional presentations on various RAS inhibitors and their effects
Revolution Medicines will host an investor webcast on October 25, 2024, focusing on PDAC data from the RMC-6236 and RMC-9805 monotherapy studies. Further updates on the company's RAS(ON) inhibitor clinical development programs will be provided later in the quarter.
Revolution Medicines (Nasdaq: RVMD) reported its Q2 2024 financial results and corporate progress. Key highlights include:
1. Advancing RMC-6236 into pivotal trials for pancreatic and lung cancer
2. Expanding RMC-6236 into earlier treatment lines
3. Progressing RMC-6291 and RMC-9805 for late-stage development
4. Appointment of Frank Clyburn to the board of directors
5. Q2 financial results: $1.59 billion cash position, $134.9 million R&D expenses, $21.7 million G&A expenses, and $133.2 million net loss
6. Reiterated 2024 GAAP net loss guidance of $560-600 million
7. Current cash can fund operations into 2027
Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its plan to release second quarter 2024 financial results on August 7, 2024, after market close. The company's senior management will host a webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and provide a corporate progress update. Interested parties can access the live webcast or replay through the company's investor relations website. The replay will be available for at least 14 days following the live event.
Revolution Medicines (Nasdaq: RVMD) announced the publication of a study in Cancer Discovery demonstrating the efficacy of their RAS(ON) multi-selective inhibitor, RMC-7977, in preclinical models of KRAS-mutated non-small cell lung cancer (NSCLC). The inhibitor showed strong anti-tumor activity alone and in combination with the RAS(ON) G12C-selective inhibitor, RMC-4998. This combination resulted in significant tumor regression and prolonged time to tumor doubling, particularly in models resistant to current therapies. The study also identified long-term tumor cell persistence mechanisms, providing insights for future treatments. Revolution Medicines plans to conduct further trials with their investigational drug RMC-6236, aimed at treating various RAS-driven cancers.
Revolution Medicines (Nasdaq: RVMD) will host an investor webcast to update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. The webcast is scheduled for July 15, 2024, at 8:00 a.m. Eastern Time. Speakers include the company's management and Dr. Brian M. Wolpin from Harvard Medical School and Dana-Farber Cancer Institute. The event can be accessed via the company's 'Events & Presentations' page. A replay will be available for 14 days post-event.
Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company focusing on targeted therapies for RAS-addicted cancers, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Mark A. Goldsmith will present at a fireside chat on June 12, 2024, at 2:40 p.m. ET. The event will be held at the Loews Miami Beach Hotel in Miami, FL, with a live webcast accessible via the company's website. A replay will be available for 14 days post-conference.
Revolution Medicines, Inc. (Nasdaq: RVMD) released its first quarter 2024 financial results and corporate progress update. The company is advancing its RAS-addicted cancer therapies, such as RMC-6236, into pivotal trials. Plans include expanding therapy reach, qualifying mutant-selective inhibitors, and exploring combination treatments. Despite revenue decline and increased expenses, the company aims to fund operations into 2027.
Revolution Medicines, Inc. (Nasdaq: RVMD) will report its financial results for the first quarter of 2024 on May 8, 2024, after market close. The company is focused on developing targeted therapies for patients with RAS-addicted cancers. A webcast hosted by senior management will discuss the financial results and corporate progress.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
What does Revolution Medicines, Inc. specialize in?
What are some of the key products in Revolution Medicines’ pipeline?
What recent achievements has Revolution Medicines reported?
What is the significance of the RMC-6236 Phase 1/1b trial?
How does the merger with EQRx benefit Revolution Medicines?
Who recently joined the board of Revolution Medicines?
What are RAS(ON) inhibitors?
How does Revolution Medicines generate insights for its drug discovery?
What are some of the ongoing trials at Revolution Medicines?
How can investors stay updated on Revolution Medicines’ developments?
